VP of Global Innovation & Director of R&D Europe, Ajinomoto Bio-Pharma Services

At the global level Eric De Vos started his current role in 2017 as VP of Global Innovation at CDMO Ajinomoto Bio-Pharma Services with primary focus on developing innovative manufacturing platforms for small molecule API, mid-size molecules, like oligonucleotides, and biological API such as proteins and antibody drug conjugates. He is the primary interface on innovation between Ajinomoto Corporate R&D teams, located at Kawasaki, Japan and the global CDMO businesses.

At the local level, since 2011 as R&D Director EU at Ajinomoto Omnichem, Belgium, he leads the 80+ person R&D and Pilot Plant experts on small molecule API process development and technical transfer to bulk manufacturing. From 2013 until 2016, he added the Pharmaceutical Fine Chemical Business unit to his responsibilities . In this role, the business unit increased profits by restructured product portfolio, improved new customer project selection, and maximized capacity utilization of pilot and commercial manufacturing units.

He joined the company in 1993 in the role of Research Project Manager leading process R&D work on small molecule APIs requiring toxic and explosive reagents like hydrazine and azides.
Eric received his doctorate in organic synthesis of C-nucleosides in 1991 from the University of Antwerp, Belgium. He enjoys sailing and breeding small freshwater fish.


17 November 2020